Trends in Psychotropic Medication Prescriptions in Urban China From 2013 to 2017

Purpose: Psychotropic medications are commonly used for treating mental disorders; however, there is currently no study on how commonly they are used in China. This study reported the trends in psychotropic medications prescriptions in urban China. Methods: A national population-based study was conducted using the China Health Insurance Research Association database to estimate the period prescription prevalence of 11 major classes of psychotropic medications annually during 2013-2017. The World Health Organization Anatomical Therapeutic Chemical (ATC) classification codes were used to identify psychotropic medications. Results: The prescription prevalence of any psychotropic medication increased from 8.110% (8.106-8.114%) in 2013 to 11.362% (11.357-11.366%) in 2017. The prescription prevalence of six classes increased significantly during 2013-2017, including sedatives-hypnotics (from 3.177 to 5.388%), anxiolytics (from 1.436 to 2.200%), antiepileptic drugs (from 1.416 to 2.140%), antipsychotics (from 0.809 to 1.156%), antidepressants (from 0.891 to 1.045%), and psycholeptic polypills (from 0.682 to 0.866%). The prescription prevalence of antidementia drugs increased from 0.069 to 0.122%, and mood stabilizers increased from 0.029 to 0.037%, although not statistically significant. The prescription prevalence of nootropic drugs, attention deficit hyperactivity disorder (ADHD) medications and drugs used in the treatment of addictive disorders was largely stable. Psychotropic medication prescription increased with age for all classes except for ADHD medications and mood stabilizers. Conclusion: Increasing trends in prescription prevalence were observed for most classes of psychotropic medications in urban China, although the prevalence was still lower than that in most developed countries. Further research is warranted to explore the potential treatment gap between China and most developed countries

Anxiety · Drug · Environmental health · Medical prescription · Mood · Mood disorders · Pharmacoepidemiology · Polypharmacy · Population · Psychiatry · Psychotropic drug · Attention Deficit Hyperactivity Disorder · Bipolar Disorder and Treatment · Medicine · Schizophrenia research and treatment · Pharmacology

• Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China

  Open Access•Longfei Jia, Yifeng Du et al.•The Lancet Public Health•2020

  Incluir item

• Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016

  Open Access•Theo Vos, Amanuel Alemu Abajobir et al.•The Lancet•2017

  Incluir item

• Global Epidemiology and Burden of Schizophrenia

  Open Access•Fiona J Charlson, Alize J Ferrari et al.•Schizophrenia Bulletin•2018

  Incluir item

• Mortality, morbidity, and risk factors in China and its provinces, 1990–2017

  Open Access•Maigeng Zhou, Haidong Wang et al.•The Lancet•2019

  Incluir item

• The Epidemiology of Depression Across Cultures

  R C Kessler, Evelyn J Bromet•Annual Review of Public Health•2013

  Incluir item

• Prevalence of mental disorders in China

  Open Access•Yueqin Huang, Yu Wang et al.•The Lancet Psychiatry•2019

  Incluir item

• Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017

  Open Access•L James, Spencer L James et al.•The Lancet•2018

  Incluir item